A Study to Evaluate Immunogenicity of Various Schedules of Inactivated Polio Vaccine

F

Fidec Corporation

Status and phase

Withdrawn
Phase 3

Conditions

Poliomyelitis

Treatments

Biological: IPV
Biological: f-IPV

Study type

Interventional

Funder types

Other

Identifiers

NCT03016949
IPV-003-ABMG

Details and patient eligibility

About

The study will evaluate the humoral immunogenicity in various schedule combinations of full dose inactivated polio vaccines (IPV) via intramuscular administration (IM) and of the fractional dose of inactivated poliovaccine (f-IPV) via intradermal administration (ID).

Full description

The study will be conducted in a setting where only IPV is being used for polio prevention in infant immunization schedules. The study population will include infants from Uruguay, a pioneer country in immunization programs in Latin America, where tOPV(trivalent oral polio vaccine) was used until 2012, after which the program changed to an all-IPV schedule without transition. The primary IPV immunization schedule in the country is as stand-alone vaccine at 2, 4 and 6 months of age, with a booster dose at 15 months. This setting allows the evaluation of IPV immunogenicity in a scenario where the circulation of any poliovirus is highly unlikely. Infants will receive two or three doses of full dose IPV IM or fractional dose f-IPV ID, in various schedule combinations (6 and 14 weeks; 10 and 14 weeks; 14 and 36 weeks; 6, 14 and 36 weeks; 10, 14 and 36 weeks). Immunological and safety assessments will be made after one dose, two doses and three doses. The study will be conducted in Montevideo, Uruguay and a total of 1493 infants will be randomized into 6 groups. Other vaccines comprise DTPw-HB-Hib (pentavalent combined diphtheria-tetanus-whole cell pertussis-hepatitis B-Hib vaccine), Pneumococcal conjugate vaccine, Rotavirus and will be administered concomitantly. Optimum immunogenicity expected from the dose/s of IPV in the post-eradication era will have to be balanced with the cost and supply constraints of IPV. This study will be critical to determine how many doses of IPV and which schedule will be recommended for the post-eradication era after the cessation of OPV (oral polio vaccine) usage globally.

Sex

All

Ages

5 to 7 weeks old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • Infants of 6 weeks of age (-7 to + 7 days) on date of first vaccination
  • Healthy, as assessed from medical history and physical examination by a study physician
  • Written informed consent obtained from parents or legal representatives that they have been properly informed about the study and are able to comply with planned study procedures

Exclusion criteria

  • Vaccinated with any poliovirus vaccine prior to inclusion
  • A household contact with OPV vaccination history in the past 4 weeks
  • HIV infection or pharmacologic immunosuppression.
  • Known allergy to any component of the study vaccines (phenoxyethanol, formaldehyde)
  • Uncontrolled coagulopathy or blood disorder contraindicating intramuscular and intradermal injections.
  • Acute severe febrile illness on day of vaccination deemed by the Investigator to be a contraindication for vaccination.
  • Not suitable for inclusion or is unlikely to comply with the protocol in the opinion of the investigator.

Trial design

0 participants in 6 patient groups

Group A
Experimental group
Description:
3 doses IPV IM at 10, 14 & 36 weeks of age incl. blood sampling at 10, 18, 36 & 40 weeks.
Treatment:
Biological: IPV
Group B
Experimental group
Description:
3 doses f-IPV ID at 10, 14 & 36 weeks of age incl. blood sampling at 10, 18, 36 & 40 weeks.
Treatment:
Biological: f-IPV
Group C
Experimental group
Description:
2 doses IPV IM at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
Treatment:
Biological: IPV
Group D
Experimental group
Description:
2 doses f-IPV ID at 14 & 36 weeks of age incl. blood sampling at 14, 18, 36 & 40 weeks.
Treatment:
Biological: f-IPV
Group E
Experimental group
Description:
3 doses IPV IM at 6, 14 & 36 weeks of age incl. blood sampling at 6, 18, 36 & 40 weeks.
Treatment:
Biological: IPV
Group F
Experimental group
Description:
3 doses f-IPV ID at 6, 14 & 36 weeks of age incl. blood sampling at 6, 18, 36 & 40 weeks.
Treatment:
Biological: f-IPV

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems